Cyr61 promotes growth of pancreatic carcinoma via nuclear exclusion of p27

Tumor Biology

Volumn 35, Issue 11, 2014, Pages 11147-11151

  Shi, Weidong ^a,b   Yin, Jianhua ^a,b   Chen, Zhen ^a,b   Chen, Hao ^a,b   Liu, Luming ^a,b   Meng, Zhiqiang ^a,b  

^a FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

^b FUDAN UNIVERSITY   (China)

Author keywords

Akt; Cyr61; ERK MAPK; p27; Pancreatic carcinoma; PI3K

Indexed keywords

CDKN1B PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE INHIBITOR 1B; CYR61 PROTEIN, HUMAN; CYSTEINE RICH PROTEIN 61; MESSENGER RNA;

APOPTOSIS; CELL NUCLEUS; CELL PROLIFERATION; GENETICS; HUMAN; METABOLISM; PANCREAS; PANCREAS TUMOR; PATHOLOGY; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL CULTURE; WESTERN BLOTTING;

APOPTOSIS; BLOTTING, WESTERN; CELL NUCLEUS; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE INHIBITOR P27; CYSTEINE-RICH PROTEIN 61; HUMANS; PANCREAS; PANCREATIC NEOPLASMS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR CELLS, CULTURED;

EID: 84927797530     PISSN: 10104283     EISSN: None     Source Type: Journal    
DOI: 10.1007/s13277-014-2423-x     Document Type: Article

References (13)

1. Han H, Von Hoff DD. Snapshot: pancreatic cancer. Cancer Cell. 2013;23:424–424 e421.
2. Lau LF. CCN1/CYR61: the very model of a modern matricellular protein. Cell Mol Life Sci. 2011;68:3149–63.
3. Chen Y, Du XY. Functional properties and intracellular signaling of CCN1/Cyr61. J Cell Biochem. 2007;100:1337–45.
4. Chaqour B, Goppelt-Struebe M. Mechanical regulation of the Cyr61/CCN1 and CTGF/CCN2 proteins. FEBS J. 2006;273:3639–49.
5. Terada N, Kulkarni P, Getzenberg RH. Cyr61 is a potential prognostic marker for prostate cancer. Asian J Androl. 2012;14:405–8.
6. Menendez JA, Mehmi I, Griggs DW, Lupu R. The angiogenic factor Cyr61 in breast cancer: molecular pathology and therapeutic perspectives. Endocr Relat Cancer. 2003;10:141–52.
7. Cheng TY, Wu MS, Hua KT, Kuo ML, Lin MT. Cyr61/CTGF/Nov family proteins in gastric carcinogenesis. World J Gastroenterol. 2014;20:1694–700.
8. Yin JH, Shi WD, Zhu XY, Chen Z, Liu LM. Qingyihuaji formula inhibits progress of liver metastases from advanced pancreatic cancer xenograft by targeting to decrease expression of Cyr61 and VEGF. Integr Cancer Ther. 2012;11:37–47.
9. Shi W, Meng Z, Chen Z, Luo J, Liu L. Proteome analysis of human pancreatic cancer cell lines with highly liver metastatic potential by antibody microarray. Mol Cell Biochem. 2011;347:117–25.
10. Shi WD, Meng ZQ, Chen Z, Lin JH, Zhou ZH, Liu LM. Identification of liver metastasis-related genes in a novel human pancreatic carcinoma cell model by microarray analysis. Cancer Lett. 2009;283:84–91.
11. Ye Q, Cai W, Zheng Y, Evers BM, She QB. ERK and AKT signaling cooperate to translationally regulate survivin expression for metastatic progression of colorectal cancer. Oncogene. 2014;33:1828–39.
12. Lieber M, Mazzetta J, Nelson-Rees W, Kaplan M, Todaro G. Establishment of a continuous tumor-cell line (panc-1) from a human carcinoma of the exocrine pancreas. Int J Cancer. 1975;15:741–7.
13. Xiao X, Gaffar I, Guo P, Wiersch J, Fischbach S, Peirish L, et al. M2 macrophages promote beta-cell proliferation by up-regulation of SMAD7. Proc Natl Acad Sci U S A. 2014;111:E1211–20.